You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immune Checkpoint Inhibitor Refractory

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer Trial (TILT-123, Pembrolizumab)

Not yet recruiting
  • Lung Cancer
  • TILT-123
  • Pembrolizumab
  • (no location specified)
Nov 5, 2023

Immune-related Colitis, Colitis Trial in Minneapolis (RMT, Placebo)

Not yet recruiting
  • Immune-related Colitis
  • Colitis
  • Minneapolis, Minnesota
    University of Minnesota
Feb 4, 2023

Immune-Mediated Colitis Trial in Montreal (Tofacitinib 10 mg)

Recruiting
  • Immune-Mediated Colitis
  • Tofacitinib 10 mg
  • Montreal, Quebec, Canada
    Sir Mortimer B Davis Jewish General Hospital - CIUSSS Centre-Oue
May 11, 2022

Solid Tumor, Adult Trial (IMSA101, Immune Checkpoint Inhibitor)

Not yet recruiting
  • Solid Tumor, Adult
  • (no location specified)
Sep 6, 2023

Solid Tumor, Hematologic Malignancy Trial in Beijing (Eliglustat, Immune checkpoint inhibitor)

Recruiting
  • Solid Tumor
  • Hematologic Malignancy
  • Beijing, China
    Department of Biotherapeutic, Chinese PLA General Hospital
Apr 28, 2022

Advanced Solid Tumor, Stereotactic Body Radiotherapy, Immune Checkpoint Inhibitor Trial in Peking (Cadonilimab, Stereotactic

Not yet recruiting
  • Advanced Solid Tumor
  • +4 more
  • Peking, Beijing, China
    Department of radiation oncology, Peking University Third Hospit
Jun 20, 2023

Metastatic Melanoma, Advanced Melanoma Trial in San Francisco (XmAb22841, XmAb23104)

Not yet recruiting
  • Metastatic Melanoma
  • Advanced Melanoma
  • San Francisco, California
    University of California, San Francisco
Jan 13, 2023

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

Completed
  • Colorectal Cancer
  • Fruquintinib combined with anti-PD-1 antibodies
  • ChangSha, Hunan, China
    Hunan Cancer Hospital
Aug 27, 2023

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

Completed
  • Metastatic Colorectal Adenocarcinoma
  • regorafenib plus anti-PD-1 antibodies
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 4, 2023

Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,

Not yet recruiting
  • Androgen-Independent Prostatic Cancer
  • +8 more
  • lorigerlimab
  • +2 more
  • (no location specified)
May 4, 2023

Solid Tumor, Immune Checkpoint Inhibitor, Intestinal Flora Trial in Guangzhou (RX-af01)

Recruiting
  • Solid Tumor
  • +2 more
  • Guangzhou, Guangdong, China
    Miao-Zhen Qiu
Oct 8, 2022

Solid Tumor, Adult Trial in United States (IMSA101, Immune checkpoint inhibitor (ICI), Immuno-oncology (IO) therapy)

Recruiting
  • Solid Tumor, Adult
  • Scottsdale, Arizona
  • +5 more
Apr 14, 2022

Colorectal Tumors Trial in Shanghai (TEC)

Recruiting
  • Colorectal Neoplasms
  • Shanghai, Shanghai, China
    Tianshu Liu
Apr 11, 2022

Adult Diffuse Large Cell Lymphoma, Recurrent, Adult Refractory DLBCL Trial in Canada (DPX-Survivac, Pembrolizumab,

Active, not recruiting
  • Adult Diffuse Large Cell Lymphoma
  • +2 more
  • DPX-Survivac
  • +2 more
  • Calgary, Alberta, Canada
  • +5 more
Nov 9, 2022

Malignant Ascites Trial in Taichung (Nivolumab, Pembrolizumab)

Enrolling by invitation
  • Malignant Ascites
  • Taichung, Please Select, Taiwan
    China Medical University Hospital
Feb 16, 2023

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma

Not yet recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +4 more
  • Biopsy
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Feb 14, 2023

Immune Checkpoint Inhibitor-related Cardiotoxicity

Not yet recruiting
  • Immune Checkpoint Inhibitors, Cardiotoxicity
  • Cardiac magnetic resonance
  • (no location specified)
Nov 10, 2023

Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)

Not yet recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +13 more
  • (no location specified)
Feb 2, 2023

Inflammatory Arthritis, Immune-related Adverse Event Trial (Adalimumab, Prednisone)

Not yet recruiting
  • Inflammatory Arthritis
  • Immune-related Adverse Event
  • (no location specified)
Sep 13, 2023

EXploring Immune-related Adverse Events of Immune checkpoinT

Active, not recruiting
  • Cancer
  • +2 more
  • Immune checkpoint inhibitor
  • Paris, France
  • +1 more
Jul 5, 2023

Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,

Completed
  • Gastrointestinal Tumor
  • Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
  • tislelizumab (BeiGene, China) combined with PD-1 inhibitor
  • Hangzhou, China
    Zhejiang Hospital
Sep 1, 2023

NSCLC Associated With Leptomeningeal Metastases Trial (Tislelizumab, pemetrexed)

Not yet recruiting
  • NSCLC Associated With Leptomeningeal Metastases
  • Tislelizumab, pemetrexed
  • (no location specified)
Nov 21, 2023

Immune Checkpoint Inhibitor Monotherapy or Combined With

Not yet recruiting
  • Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular Carcinoma
  • Immune checkpoint inhibitor
  • Guangzhou, Guangdong, China
    Department of Minimally Invasive and Interventional Radiology, L
Jan 30, 2023

Determine Pro-Inflammatory Cytokine Kinetics During Immune

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Melanoma
    • Indianapolis, Indiana
      Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
    Jan 30, 2023

    Lung Squamous Cell Carcinoma Trial in Yancheng (To explore the efficacy and safety of immune checkpoint inhibitor combined with

    Recruiting
    • Lung Squamous Cell Carcinoma
    • To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
    • Yancheng, Jiangsu, China
      Yancheng Clinical College of Xuzhou Medical University
    Mar 21, 2023